to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing upon the distinctive metabolic processes of cancer cells. Learn More...Cornerstone Pharmaceuticals Cornerstone Pharmaceuticals A Singular Focus on Cancer Metabolism About Overview Leadership Non-Executive Directors Advisory Board Members Cancer... Scientific Papers and Abstracts Careers Contact Revolutionizing the way cancer is treated. Learn More Targeting Cancer Metabolism Learn More News View All September 28, 2012 Cornerstone...

Pipeline Cornerstone Pharmaceuticals A Singular Focus on Cancer Metabolism About Overview Leadership Non-Executive Directors Advisory Board Members Cancer Metabolism Overview Our... and Abstracts Careers Contact Home > Platforms & Pipelines > Pipeline Pipeline Cornerstone Pharmaceuticals is working to translate the company s scientific insights on cancer metabolism... into clinical interventions as quickly, safely and effectively as possible. Cornerstone s unique approach offers significant hope for transforming cancer treatment, and its scientists...

/II Combination Therapy Clinical Trial of CPI-613 for Treatment of Pancreatic Cancer September 24, 2008 Cornerstone Pharmaceuticals Announces Initiation of Clinical Trials of CPI-613...Press Releases Cornerstone Pharmaceuticals Cornerstone Pharmaceuticals A Singular Focus on Cancer Metabolism About Overview Leadership Non-Executive Directors Advisory Board... Members Cancer Metabolism Overview Our Approach Platforms & Pipelines Pipeline AEMD/CPI-613 Emulsiphan/EmPAC Clinical Trials News & Media Press Releases News Coverage Press Kit Press...

Press Releases Cornerstone Pharmaceuticals Cornerstone Pharmaceuticals A Singular Focus on Cancer Metabolism About Overview Leadership Non-Executive Directors Advisory Board... Members Cancer Metabolism Overview Our Approach Platforms & Pipelines Pipeline AEMD/CPI-613 Emulsiphan/EmPAC Clinical Trials News & Media Press Releases News Coverage Press Kit Press... engagement of Dr. Paul Bingham at the Tenth Annual Discovery On Target Conference in Boston regarding cancer cell metabolism September 24, 2012 Cornerstone Pharmaceuticals announces...

with CPI-613 for refractory cancers. In our ongoing Phase I 002 trial, patients with solid tumors for whom there is no available therapy were treated with CPI-613 as a single agent...ESMO: 2010 Cornerstone Pharmaceuticals A Singular Focus on Cancer Metabolism About Overview Leadership Non-Executive Directors Advisory Board Members Cancer Metabolism Overview... and Abstracts Careers Contact Home > News & Media ESMO: 2010 A First in Class AEMD to Combat Cancer Authors: R.C. Shepard1, K. Lee2, R. Shorr2, B. Rodriguez2, C. Maturo2, K. Gelmon3, K...